FAQs about Zeposia
Zeposia was approved by the U.S. Food and Drug Administration in March 2020 for the treatment of adults with relapsing forms of multiple sclerosis (MS). Indications for use include relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome. Zeposia also is approved in the U.S. for ulcerative colitis, an inflammatory bowel disease.
Zeposia is not recommended for pregnant patients as it may cause harm to a developing fetus. Patients who plan or are able to become pregnant should use contraception methods while on Zeposia and for three months after stopping treatment.
There are no known interactions between Zeposia and alcohol. However, because alcohol may interfere with some disease symptoms and medications, patients are advised to discuss safe alcohol consumption with their healthcare provider.
Results may be seen in as little as three months. In the RADIANCE Part A trial, which compared Zeposia against a placebo in patients with relapsing forms of multiple sclerosis (MS), a significant increase in the number of patients without inflammatory brain lesions was evident with Zeposia treatment as soon as 12 weeks after the therapy’s start. However, because MS affects each person differently, patients should discuss with their healthcare teams how the medication can help in their specific case.
Neither hair loss nor weight gain was reported in clinical trials as side effects of Zeposia. Patients who experience such effects after starting on the medication should discuss these issues with their healthcare providers.